Nabi Biopharmaceuticals provides update on bacterial infections programs and Cytokinetics files $100 million shelf.

0 Comments | M2 Presswire, June, 2005

M2 PRESSWIRE-15 June 2005-US Financial Network: Nabi Biopharmaceuticals provides update on bacterial infections programs and Cytokinetics files $100 million shelf(C)1994-2005 M2 COMMUNICATIONS LTD RDATE:16062005 City of Industry, CA - Biotechnology industry news provide by Financial News USA (OTC: FNWU).

Nabi Biopharmaceuticals (Nasdaq: NABI) continues to make significant progress in advancing its comprehensive approach to prevent and treat serious bacterial infections. Several significant developments will be discussed in more detail during its June 16, 2005 Investor/Analyst Day at the Millennium Hotel in New York City. The Immune Response Corporation (Nasdaq: IMNR), a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in...

Read the rest of this article with a Free Trial at HighBeam Research.
Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research
 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:
  1. You are currently: a Guest |
  4.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)